Biotechnology major BioCon is likely to take its group entity Biocon Biologics public and is expected to raise about $500M.
Biotechnology major BioCon is likely to take its group entity Biocon Biologics public and is expected to raise about $500 million. Sources close to the company said that the new entity will need huge investments to fund clinical development and it could go up to $500 million.
Biocon recently received shareholders’ approval to the resolution for transfer of biosimilar business by slump sale to Biocon Biologics India.
